drugset / Trial / NCT05492682
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.
Timeline
- Start
- 2023-02-02
- Primary completion
- 2027-04-30
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | PeptiCRAd-1 | Unknown | — | Other |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |